Want to join the conversation?
$IR expects revenues to grow 1-2% in 2016. The company expects continuing EPS of $5.47-5.57, including a $0.05 loss for restructuring and $1.52 from the gain on the sale of Hussmann. Adjusted EPS from continuing operations is expected to be in the range of $4.00-4.10 in 2016, compared with prior guidance of $3.95-4.10.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)